Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters.

Semin Hematol

The Multiple Myeloma Research Foundation, Norwalk, CT; Multiple Myeloma Center of Excellence, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Published: October 2024

In the United States, Black people experience multiple myeloma (MM) at a frequency that is more than double that of White people and experience much higher rates of mortality. Despite bearing a disproportionate impact of both MM incidence and mortality, Black patients are significantly underrepresented in most MM clinical trials. This is in part because Black patients experience a higher prevalence of hemoglobinopathies and Duffy-null phenotype, which affect hemoglobin and neutrophil levels, respectively, potentially excluding patients from clinical trials. The Multiple Myeloma Research Foundation (MMRF) has convened a series of Health Equity Summits that include a focus on creating inclusive clinical trials for MM. The present paper, an output of the most recent workshop, focuses on the role of laboratory reference ranges as a barrier to clinical trial participation and offers tangible steps to improve the enrollment of a diverse and representative population.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2024.10.008DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
12
clinical trials
12
clinical trial
8
people experience
8
experience higher
8
black patients
8
clinical
5
modernizing multiple
4
myeloma clinical
4
trial eligibility
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!